{"doi":"10.1167/tvst.13.3.1","title":"Peripapillary Atrophy Area as an Indicator of Glaucomatous Structural and Functional Progression","abstract":"Purpose: To determine whether peripapillary atrophy (PPA) area is an indicator of glaucomatous structural and functional damage and progression. Methods: In this retrospective longitudinal analysis from ongoing prospective study we qualified 71 eyes (50 subjects) with glaucoma. All subjects had a comprehensive ophthalmic examination, visual field (VF), and spectral-domain optical coherence tomography (OCT) testing in at least three visits. PPA was manually delineated on en face OCT optic nerve head scans, while observing the corresponding cross-sectional images, as the hyper-reflective area contiguous with the optic disc. Results: The mean follow-up duration was 4.4 ± 1.4 years with an average of 6.8 ± 2.2 visits. At baseline, PPA area was significantly associated only with VF's mean deviation (MD; P = 0.041), visual field index (VFI; P = 0.041), superior ganglion cell inner plexiform layer (GCIPL; P = 0.011), and disc area (P = 0.011). Longitudinally, PPA area was negatively and significantly associated with MD (P = 0.015), VFI (P = 0.035), GCIPL (P = 0.009), superior GCIPL (P = 0.034), and disc area (P = 0.007, positive association). Conclusions: Longitudinal change in PPA area is an indicator of glaucomatous structural and functional progression but PPA area at baseline cannot predict future progression. Translational Relevance: Longitudinal changes in peripapillary atrophy area measured by OCT can be an indicator of structural and functional glaucoma progression.","journal":"Translational Vision Science & Technology","year":2024,"id":464967,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7686,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":6881,"name":"Joel S. Schuman","orcid":"0000-0002-8885-3766","position":1,"is_corresponding":false},{"id":834769,"name":"TingFang Lee","orcid":null,"position":2,"is_corresponding":false},{"id":817092,"name":"Zeinab Ghassabi","orcid":"0000-0003-1304-825X","position":3,"is_corresponding":false},{"id":583206,"name":"Ronald Zambrano","orcid":"0000-0002-6582-5308","position":4,"is_corresponding":false},{"id":246046,"name":"Jiyuan Hu","orcid":"0000-0003-1332-5587","position":5,"is_corresponding":false},{"id":542835,"name":"Hiroshi Ishikawa","orcid":"0000-0001-6310-5748","position":6,"is_corresponding":false},{"id":6888,"name":"Gadi Wollstein","orcid":"0000-0001-7036-2726","position":7,"is_corresponding":false},{"id":1296134,"name":"Fábio Lavinsky","orcid":"0000-0002-6925-1794","position":8,"is_corresponding":false},{"id":1296514,"name":"Maroun Khreish","orcid":null,"position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T02:04:46.201722Z","pmid":"38427349","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}